A Case Report:Severe Bullous Skin Reaction Induced by Anti-PD-1 Antibody(Toripalimab)Therapy in a Patient with Thymic Carcinoma  

作　　者：Chong TENG Xiaowei SONG Chengjuan FAN Yashuang ZHAO Lina DU Siqi MAN Yuanyuan HU Zhengjun JIANG Tao XIN 

机构地区：[1]Department of Oncology,the Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150028,China [2]Department of Epidemiology,College of Public Health,Harbin Medical University Harbin,Heilongjiang 150028,China

出　　处：《Clinical Cancer Bulletin》2022年第3期172-175,共4页临床癌症通报（英文）

摘　　要：The development of immune checkpoint inhibitors,such as those targeting programmed cell death protein 1(PD-1),represents a major breakthrough in cancer therapy.Although immune checkpoint blockade therapy has a favorable risk/benefit ratio,it causes significant immune-related adverse events(irAEs),such as cutaneous reactions,in particular,severe bullous skin reactions and toxic epidermal necrolysis.Here,we report a case of a 51-year-old woman with malignant thymoma who developed a severe bullous skin reaction(characterized by a systemic rash,bullae,epidermal desquamation,and Stevens-Johnson syndrome)as a result of treatment with the PD-1 inhibitor toripalimab.The patient was treated with high doses of glucocorticoid,intravenous immunoglobulin,and intensive care,and eventually recovered from the severe irAEs.The intravenous injection of anti-PD-1 antibodies induces cutaneous reactions,which are associated with higher mortality rates.High doses of glucocorticoid combined with intravenous immunoglobulin are effective in alleviating such irAEs.Thus,improving the level of care and preventing skin infections can effectively reduce the risk of death.

关 键 词：PD-1 inhibitor thymic carcinoma toripalimab immune-related adverse events severe bullous skin reactions toxic epidermal necrolysis Stevens-Johnson syndrome case report 

分 类 号：R736.3[医药卫生—肿瘤]